To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
A double-blind placebo controlled, randomized, Phase 2b study to evaluate the efficacy and
safety of once-daily, oral administration of 80 or 160 mg HSK31679 versus matching placebo in
Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis.